BIOMAT Database Logo BIOMAT Database Logo

Ifosfamide extrapyramidal neurotoxicity. 1992

M G Pallotta, and A Velazco, and A Sadler

UI MeSH Term Description Entries
D007069 Ifosfamide Positional isomer of CYCLOPHOSPHAMIDE which is active as an alkylating agent and an immunosuppressive agent. Isofosfamide,Isophosphamide,Asta Z 4942,Holoxan,Iphosphamide,Iso-Endoxan,NSC-109,724,NSC-109724,Iso Endoxan,NSC 109,724,NSC 109724,NSC109,724,NSC109724
D008297 Male Males
D005116 Extrapyramidal Tracts Uncrossed tracts of motor nerves from the brain to the anterior horns of the spinal cord, involved in reflexes, locomotion, complex movements, and postural control. Extrapyramidal Tract,Tract, Extrapyramidal
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D001480 Basal Ganglia Diseases Diseases of the BASAL GANGLIA including the PUTAMEN; GLOBUS PALLIDUS; claustrum; AMYGDALA; and CAUDATE NUCLEUS. DYSKINESIAS (most notably involuntary movements and alterations of the rate of movement) represent the primary clinical manifestations of these disorders. Common etiologies include CEREBROVASCULAR DISORDERS; NEURODEGENERATIVE DISEASES; and CRANIOCEREBRAL TRAUMA. Extrapyramidal Disorders,Basal Ganglia Disorders,Lenticulostriate Disorders,Basal Ganglia Disease,Basal Ganglia Disorder,Extrapyramidal Disorder,Lenticulostriate Disorder

Related Publications

M G Pallotta, and A Velazco, and A Sadler
Ifosfamide extrapyramidal neurotoxicity.
July 1991, Cancer,
M G Pallotta, and A Velazco, and A Sadler
Delayed Ifosfamide Neurotoxicity.
January 2020, American journal of therapeutics,
M G Pallotta, and A Velazco, and A Sadler
Ifosfamide-induced neurotoxicity.
September 1991, Gynecologic oncology,
M G Pallotta, and A Velazco, and A Sadler
Aprepitant-associated ifosfamide neurotoxicity.
June 2010, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners,
M G Pallotta, and A Velazco, and A Sadler
Suspected ifosfamide-induced neurotoxicity.
December 1999, Pharmacotherapy,
M G Pallotta, and A Velazco, and A Sadler
Ifosfamide neurotoxicity in children.
March 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
M G Pallotta, and A Velazco, and A Sadler
Ifosfamide pharmacokinetics and neurotoxicity.
January 1990, Lancet (London, England),
M G Pallotta, and A Velazco, and A Sadler
Extrapyramidal system neurotoxicity: animal models.
January 2015, Handbook of clinical neurology,
M G Pallotta, and A Velazco, and A Sadler
Hallucinations and ifosfamide-induced neurotoxicity.
March 1994, Cancer,
M G Pallotta, and A Velazco, and A Sadler
Ifosfamide stereoselective dichloroethylation and neurotoxicity.
April 1994, Lancet (London, England),
Copied contents to your clipboard!